
Elevated cancer risk traced back to popular appliance found in millions of American homes
A new study found that gas stove emissions result in a significantly increased cancer risk that is up to 16 times greater for kids than adults.
The Stanford-led team investigated the health impacts of the top five percent highest benzene-emitting gas stoves, which are used by 6.3million Americans.
Benzene is a known carcinogen that has been linked to multiple types of cancer, particularly leukemia. The World Health Organization (WHO) states that there is no safe level of long-term exposure to benzene.
These stoves emit benzene gas as they burn propane or natural gas. When inhaled, this toxic chemical causes changes to cellular function that can result in cancer and other health issues.
The team looked at benzene exposure in types of homes, finding apartments had the highest cancer risk, followed by attached homes, manufactured homes and then detached homes when there was high stove use and no ventilation.
According to the researchers, in non-ventilated apartments with high gas stove use, up to 16 out of every one million children could develop cancer from long-term benzene exposure.
For adults living in the same conditions, the risk is also significant, with up to eight out of every one million potentially developing cancer.
This is well above the WHO's safety limit for the carcinogenic effect of benzene, set at one case per one million people, which suggests these stoves may be driving a public health crisis.
Based on the fact that 6.3 million people in the US may be exposed to elevated benzene from gas stoves, the researchers estimate there could be 16 to 69 extra leukemia cases per year.
The team defined medium usage as using one burner in the morning and two in the evening for 30 minutes each, without the oven, reflecting typical daily cooking.
High usage involved more intense cooking: two burners in the morning, four in the evening (41 minutes each), plus oven use at 350°F for over two hours.
The researchers used past studies to estimate how much benzene is released during low, medium, and high cooking scenarios, then modeled exposure levels across different types of homes and ventilation scenarios.
By analyzing all these factors, the team determined how much benzene people who use these stoves are breathing in, depending on the room they're in, how long they stay there and how often they cook.
The researchers found that in non-ventilated settings with high stove use, benzene levels in kitchens peaked between 1.7 and 3.35 parts per billion (ppb), which is well above California's safety limit of 1 ppb.
But this toxic pollutant isn't just found in kitchens. After one to two hours of cooking, the researchers found that it wafts into other parts of the home too, including bedrooms.
This is particularly dangerous due to the amount of time people spend in bedrooms.
Apartments, especially small ones, had the highest bedroom concentrations at 3.3 ppb, but other housing types showed alarmingly high levels too, all of which were above the 1 ppb safety limit.
Proper ventilation significantly reduced these exposure levels. Using a high-efficiency stove hood reduced daily kitchen benzene levels by 0.21 ppb on average, and keeping all windows open throughout the day cut levels by up to 99 percent.
Even having windows open for just a few hours per day reduced benzene exposure by up to 42 percent.
Under low or medium stove use most homes stayed below the 1 ppb threshold, even without sufficient ventilation.
Based on these exposure levels, the researchers calculated the cancer risks for both adults (aged 18 to 65) and children (aged one to 17).
The researchers found that ventilation reduced, but did not eliminate, cancer risk. Only the extreme case of keeping windows open all day brought risks close to acceptable levels.
Based on these findings, the team estimated 16 to 69 excess cases cased of leukemia per year among Americans who have these stoves and fall into the 'high-use' category. What's more, these cases are mostly among children.
For those who fall into the 'medium-use' category, they estimate an excess 10 cases per year.
Although these numbers are based on estimates rather than actual case data, they point to a significantly elevated health risk for gas stove users, especially for kids.
'Overall, this study underscores the importance of effective ventilation and highlights the need for policies and strategies to mitigate benzene exposure from gas stoves, particularly for vulnerable populations such as children,' the researchers concluded.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Daily Mirror
an hour ago
- Daily Mirror
Mounjaro weight loss drug price to surge by 170% for Brits - except for ONE customer
Eli Lilly is increasing the UK price of its weight-loss drug Mounjaro Eli Lilly is set to significantly hike the UK price of its weight-loss and diabetes medication Mounjaro, with some dosages expected to see a staggering 170 percent increase starting from September. The pharmaceutical giant has justified the price surge as an effort to "address pricing inconsistencies compared with other developed countries, including in Europe" and to ensure equitable global contributions towards funding medical research. The sharpest rise will affect the month's supply of the drug's highest doses, which will soar from £122 to £330. Smaller doses will experience increases ranging from 45 to 138 percent. It comes after a man, 30, puts shoulder pain down to gym aches, then doctors ask where he'd like to die. Despite these changes, Lilly has assured that the NHS will not be affected by the new list prices, pledging to maintain the current rates to preserve uninterrupted patient access. Private healthcare providers, who also offer the medication, will face the new prices but have the option to negotiate confidential discounts directly with Eli Lilly. This development occurs amidst political debates in the US, where ex-president Donald Trump has lambasted what he deems "foreign freeloaders" for enjoying lower pharmaceutical costs while Americans bear much higher expenses. In one address, he highlighted obesity treatments, recounting how a friend in London acquired the "fat shot drug" at a fraction of the US cost, reports the Daily Record. Research from the Rand Corporation indicates that drug prices in the US are typically almost triple those in several other advanced nations. The pharmaceutical sector has been mobilising to combat the potential danger of a "most favoured nation" strategy, which could tie American pricing to international rates. Lilly highlighted that the UK was amongst the earliest markets to receive Mounjaro and emphasised that its initial focus had been on delivering the medication to diabetic patients swiftly. "At launch, Lilly agreed to a UK list price that is significantly below the European average to prevent delays in NHS changes in the environment and new clinical evidence supporting the value of Mounjaro, we are now aligning the list price more consistently to ensure fair global contributions to the cost of innovation," the firm stated. Talks between pharmaceutical companies and the UK Government regarding NHS drug costs have grown increasingly fraught, with deliberations about modifications to a clawback levy on pharmaceutical sales extending well beyond agreed timelines. The Government's latest proposals featured plans to increase spending on medications, though industry chiefs voiced exasperation over the absence of specifics or clarity regarding whether this would involve purchasing additional medicines or paying elevated prices for current treatments. The National Institute for Health and Care Excellence (NICE) has endorsed Mounjaro for as many as 3.4 million individuals across England. Nevertheless, worries about cost-effectiveness resulted in an arrangement for a staged introduction, beginning with approximately 250,000 patients presenting the most urgent clinical requirements during the initial three years. NHS England has assured that the forthcoming price alterations will not impact the provision of the medication to qualified patients suffering from obesity or diabetes. "Mounjaro is a cost-effective and valuable tool to support people to reach a healthier weight and the wider health and lifestyle benefits that offers," NHS England stated. The adjustments bring the UK's pricing more in line with the European mean, occurring amidst a period when drug manufacturers are acutely aware of how varying international prices might influence upcoming policy choices in the US.


Times
3 hours ago
- Times
Brain chip could translate thoughts into speech
Technology with the ability to decode a person's inner thoughts and translate them into speech in real time has moved a step closer after the testing of a new brain implant, scientists have claimed. Researchers at Stanford University in California said that their device was able, with 74 per cent accuracy, to detect a person's 'inner speech' — where they imagined saying a specified set of words in their mind without any effort to physically utter them — and decipher which words they were thinking about. They said that it could represent a breakthrough for people with various forms of paralysis or impairments that prevent them from speaking unaided and could one day 'restore communication that is as fluent, natural and comfortable as conversational speech'.


Daily Record
8 hours ago
- Daily Record
Price of weight loss drug Mounjaro to rise - how much more users will pay
Eli Lilly will raise UK prices for Mounjaro by up to 170 percent to 'address pricing inconsistencies compared with other developed countries, including in Europe' Eli Lilly is sharply increasing the UK price of its weight-loss and diabetes drug Mounjaro, with the cost of some doses set to rise by as much as 170 percent from September. The pharmaceutical company said the move is intended to 'address pricing inconsistencies compared with other developed countries, including in Europe' and ensure a fairer global contribution to funding medical innovation. The most dramatic increase will see the month's supply of the highest doses of the drug jump from £122 to £330. Lower doses will rise by between 45 and 138 percent. However, Lilly stressed that the new list prices will not apply to the NHS, with the company continuing to supply the health service at the existing rate to avoid disrupting patient access. Private healthcare providers, who also prescribe the drug, will be subject to the increase but can negotiate confidential discounts with the company. The move comes against the backdrop of political pressure from the United States, where former president Donald Trump has criticised what he calls 'foreign freeloaders' benefiting from lower drug prices abroad while Americans pay substantially more. In a speech, he singled out obesity treatments, saying a friend in London had bought the 'fat shot drug' for far less than in the US. Research by the Rand Corporation suggests that US drug prices are, on average, almost three times higher than those in many other advanced economies. The pharmaceutical industry has been working to counter the potential threat of a 'most favoured nation' policy, which could peg American prices to those charged internationally. Lilly noted that the UK was one of the first markets where it launched Mounjaro and said its initial priority had been to get the medicine to diabetes patients quickly. 'At launch, Lilly agreed to a UK list price that is significantly below the European average to prevent delays in NHS availability. With changes in the environment and new clinical evidence supporting the value of Mounjaro, we are now aligning the list price more consistently to ensure fair global contributions to the cost of innovation,' the company said. Negotiations between drugmakers and the UK government over NHS medicine costs have been tense, with discussions about changes to a clawback tax on drug sales dragging past agreed deadlines. The government's most recent proposals included plans to spend more on medicines, but industry leaders expressed frustration at the lack of detail or clarity on whether this would mean buying more medicines or paying higher prices for existing ones. The National Institute for Health and Care Excellence (NICE) has recommended Mounjaro for up to 3.4 million people in England. Join the Daily Record WhatsApp community! Get the latest news sent straight to your messages by joining our WhatsApp community today. You'll receive daily updates on breaking news as well as the top headlines across Scotland. No one will be able to see who is signed up and no one can send messages except the Daily Record team. All you have to do is click here if you're on mobile, select 'Join Community' and you're in! If you're on a desktop, simply scan the QR code above with your phone and click 'Join Community'. We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don't like our community, you can check out any time you like. To leave our community click on the name at the top of your screen and choose 'exit group'. If you're curious, you can read our Privacy Notice. However, concerns over affordability led to an agreement for a phased rollout, starting with around 250,000 patients who have the highest clinical need over the first three years. NHS England confirmed that the upcoming price changes would not affect how it provides the drug to eligible patients with obesity or diabetes. 'Mounjaro is a cost-effective and valuable tool to support people to reach a healthier weight and the wider health and lifestyle benefits that offers,' it said. The changes place the UK price closer to the European average and come at a time when pharmaceutical companies are increasingly conscious of how international price differences could shape future US policy decisions.